Metabolic Effect of Blocking Sodium-Taurocholate Co-Transporting Polypeptide in Hypercholesterolemic Humans with a Twelve-Week Course of Bulevirtide—An Exploratory Phase I Clinical Trial
Bile acids (BA) play an important role in cholesterol metabolism and possess further beneficial metabolic effects as signalling molecules. Blocking the hepatocellular uptake of BA via sodium-taurocholate co-transporting polypeptide (NTCP) with the first-in-class drug bulevirtide, we expected to obse...
Main Authors: | Felicitas Stoll, Andrea Seidel-Glätzer, Ina Burghaus, Oliver Göring, Max Sauter, Peter Rose, Volker Daniel, Mathias Haag, Matthias Schwab, Johannes Riffel, Florian André, Lenka Taylor, Johanna Weiss, Jürgen Burhenne, Volker Cleeves, Walter E. Haefeli, Antje Blank |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-12-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/23/24/15924 |
Similar Items
-
Is Combined Bulevirtide and Pegylated Interferon Therapy for Chronic Hepatitis D Superior over Bulevirtide Monotherapy?
by: V. E. Syutkin, et al.
Published: (2020-09-01) -
Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV/HDV
by: Roberto Mateo, et al.
Published: (2023-11-01) -
Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteers
by: Vanessa Zhu, et al.
Published: (2023-04-01) -
Treatment of Chronic Hepatitis D with Bulevirtide—A Fight against Two Foes—An Update
by: Peter Ferenci, et al.
Published: (2022-11-01) -
Troglitazone Impedes the Oligomerization of Sodium Taurocholate Cotransporting Polypeptide and Entry of Hepatitis B Virus Into Hepatocytes
by: Kento Fukano, et al.
Published: (2019-01-01)